Drug intelligence / Profile preview

CFS2212

Development stage: Preclinical
Lead developer: Zhongke CELFULL
Modality: Small Molecules

Overview

CFS2212 is a preclinical therapeutic candidate developed by Zhongke CELFULL Mitochondrial Medicine for the treatment of COVID-19 related fatigue syndrome. As part of the company's mitochondrial medicine platform, CFS2212 is designed to address mitochondrial dysfunction and cellular energy metabolism deficits, which are considered significant contributors to the persistent fatigue observed in patients with Long COVID. The drug is categorized as a therapeutic candidate, distinguishing it from the developer's line of nutraceutical and skincare products, and is currently undergoing preclinical evaluation.

Beyond the preview

Go deeper on CFS2212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CFS2212.

Explore the full profile